Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment

Petakh et al., MDPI AG, doi:10.20944/preprints202304.1127.v1
Apr 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 87 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 120 hospitalized COVID-19 patients showing lower alpha diversity of gut microbiota associated with antibiotic use, type 2 diabetes, longer hospital stays, higher CRP levels, and higher NLR. Metformin therapy was associated with increased alpha diversity. There was no significant difference in diversity between delta and omicron groups. Authors suggest that maintaining a diverse gut microbiota may benefit COVID-19 patients with type 2 diabetes.
Petakh et al., 28 Apr 2023, Ukraine, preprint, 5 authors. Contact: pavlo.petakh@uzhnu.edu.ua (corresponding author), kamyshnyi_om@tdmu.edu.ua.
This PaperMetforminAll
Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment
Pavlo Petakh, Iryna Kamyshna, Valentyn Oksenych, Denis Kainov, Aleksandr Kamyshnyi
doi:10.20944/preprints202304.1127.v1
The gut microbiota plays a crucial role in maintaining host health and has a significant impact on human health and disease. In this study, we investigated the alpha diversity of gut microbiota in COVID-19 patients and analyzed the impact of COVID-19 variants, antibiotic treatment, type 2 diabetes (T2D), and metformin therapy on gut microbiota composition and diversity. We used a culture-based method to analyze the gut microbiota and calculated alphadiversity using the Shannon H' and Simpson 1/D indices. We collected clinical data, such as length of hospital stay (LoS), C-reactive protein (CRP) levels, and neutrophil-to-lymphocyte ratio. We found that patients with T2D had significantly lower alpha-diversity than those without T2D. Antibiotic use was associated with a reduction in alpha-diversity, while metformin therapy was associated with an increase. We did not find significant differences in alpha-diversity between the Delta and Omicron groups. Length of hospital stay, CRP levels, and NLR showed weak to moderate correlations with alpha diversity. Our findings suggest that maintaining a diverse gut microbiota may benefit COVID-19 patients with T2D. Interventions aimed at preserving or restoring gut microbiota diversity, such as avoiding unnecessary antibiotic use and promoting metformin therapy, may improve patient outcomes.
Author Contributions: Conceptualization, A.K.; methodology, A.K. and P.P..; software, A.K. and P.P.; validation, A.K., P.P. and I.K.; formal analysis, I.K.; investigation, P.P.; resources, A.K.; data curation, A.K.; writing-original draft preparation, P.P.; writing-review and editing, A.K., V.O., D.K.; visualization, P.P. and A.K.; supervision, A.K.; project administration, A.K.. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Uzhhorod National Univesrity (11.02.20/11ab) Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Conflicts of Interest: The authors declare no conflict of interest.
References
Bernard-Raichon, Venzon, Klein, Axelrad, Zhang et al., Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia, Nature Communications
Buchynskyi, Kamyshna, Lyubomirskaya, Moshynets, Kobyliak et al., Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
De La Cuesta-Zuluaga, Mueller, Corrales-Agudelo, Velásquez-Mejía, Carmona et al., Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut, Diabetes Care
Hou, Wu, Chen, Wang, Zhang et al., Microbiota in health and diseases, Signal Transduction and Targeted Therapy
Hussain, Cher, Abid, Abid, Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential, Front Immunol
Ianevski, Ahmad, Anunnitipat, Oksenych, Zusinaite et al., Seven classes of antiviral agents, Cellular and Molecular Life Sciences
Ianevski, Simonsen, Myhre, Tenson, Oksenych et al., DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs), Nucleic acids research
Ianevski, Yao, Simonsen, Myhre, Ravlo et al., Mono-and combinational drug therapies for global viral pandemic preparedness, iScience
Kamyshnyi, Koval, Kobevko, Buchynskyi, Oksenych et al., Therapeutic Effectiveness of Interferon-&alpha;2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience
Kamyshnyi, Matskevych, Lenchuk, Strilbytska, Storey et al., Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential, Biomedicine & Pharmacotherapy
Patangia, Ryan, Dempsey, Ross, Stanton, Impact of antibiotics on the human microbiome and consequences for host health, MicrobiologyOpen
Petakh, Griga, Mohammed, Loshak, Poliak et al., Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes, Medical archives
Petakh, Isevych, Mohammed, Loshak, Poliak et al., Association between Use of Metformin and Insulin with Hematological Parameters in COVID-19 Patients with Type 2 Diabetes: A Single Center, Cross-Sectional Study, Clinical Diabetology
Petakh, Kamyshna, Nykyforuk, Yao, Imbery et al., Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword, J Viruses
Petakh, Kobyliak, Kamyshnyi, Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method
Pircalabioru, Grigore, Barbu, Chifiriuc, Savu, Impact of COVID-19 on the Microbiome and Inflammatory Status of Type 2 Diabetes Patients, Biomedicines
Rebelo, Domingues, Dionisio, Gomes, Botelho et al., COVID-19 Lockdowns May Reduce Resistance Genes Diversity in the Human Microbiome and the Need for Antibiotics, International journal of molecular sciences
Righi, Lambertenghi, Gorska, Sciammarella, Ivaldi et al., Impact of COVID-19 and Antibiotic Treatments on Gut Microbiome: A Role for Enterococcus spp, J Biomedicines
Romani, Chierico, Macari, Pane, Ristori et al., The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection, Front Cell Infect Microbiol
Thursby, Juge, Introduction to the human gut microbiota, The Biochemical journal
Valentini, Piermattei, Sante, Migliara, Delogu, Immunomodulation by Gut Microbiota: Role of Toll-Like Receptor Expressed by T Cells, Journal of Immunology Research
Wu, Esteve, Tremaroli, Khan, Caesar et al., Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug, Nature medicine
Yin, Minacapelli, Parmar, Catalano, Bhurwal et al., Alterations of the fecal microbiota in relation to acute COVID-19 infection and recovery, Molecular biomedicine
Zhang, Hu, Metabolic Syndrome, Targets O, Therapy. Effects of metformin on the gut microbiota in obesity and type 2 diabetes mellitus
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit